Open AccessTenofovir: what have over 1 million years of patient experience taught us?
Author(s) -
Pozniak A.
Publication year - 2008
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/j.1742-1241.2008.01817.x
Subject(s) - stavudine , medicine , tenofovir , lipoatrophy , regimen , zidovudine , human immunodeficiency virus (hiv) , clinical trial , nucleoside , lamivudine , pharmacology , virology , antiretroviral therapy , virus , viral load , viral disease , chemistry , stereochemistry , hepatitis b virus
Summary Several groundbreaking trials and over 1 million years of patient experience have established tenofovir as an important component of HIV treatment. Tenofovir has demonstrated potent antiviral efficacy, with a low risk of developing resistance when used as part of an effective combination regimen. It is generally well tolerated, with a low risk of lipoatrophy and a favourable effect on lipid profile compared with older nucleoside analogue agents such as stavudine or zidovudine. Clinical data suggest that switching from thymidine analogues to a tenofovir‐containing regimen can benefit patients with lipid abnormalities or lipoatrophy. This article reviews the development of tenofovir, including pivotal studies that have influenced HIV clinical practice.